This research, according to experts, may lead to the discovery of a new drug which can combat the ill-effects of cisplatin, a widely used chemotherapy drug for treatment of cancer.
"The research study has evaluated the usefulness of epicatechin gallate (ECG), a polyphenolic compound obtained from green tea, in preventing the damage of kidneys induced by cisplatin. Side effects of cisplatin may include nephrotoxicity and life-threatening damaged kidneys.
"This identification has the potential to be developed into a therapeutic drug to counter the side-effects of cisplatin," said Dr Y K Gupta, Head of Department (Pharmacology), AIIMS.
"Approximately 30 per cent of the treated patients may develop nephrotoxicity after receiving an initial dose of cisplatin. Cisplatin causes production of free radicals inside cells in kidney which leads to oxidative stress and inflammation.
"The therapeutic procedures such as vigorous hydration with normal saline and forced diuresis have limited efficacy in reducing kidney damage. Further, at present no specific drug is available which can prevent or attenuate the kidney damage due to cisplatin," said Bhatia.
"In our study, we observed that ECG obtained from green tea significantly reduced kidney injury due to cisplatin. It was most effective at the dose of 5 mg/kg and was administered to rats through injection for 10 days. Further, ECG reduced inflammation and cell death (apoptosis) in rats," she said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
